Send to

Choose Destination
See comment in PubMed Commons below
Bone Marrow Transplant. 2016 Feb;51(2):273-6. doi: 10.1038/bmt.2015.247. Epub 2015 Oct 19.

The use of basiliximab-infliximab combination for the treatment of severe gastrointestinal acute GvHD.

Author information

Department of Pharmacy Services, Smilow Cancer Hospital at Yale-New Haven Hospital, New Haven, CT, USA.
Department of Internal Medicine, Section of Hematology, Yale-New Haven Hospital, New Haven, CT, USA.


After allogeneic stem cell transplant, severe grade III-IV gastrointestinal (GI) acute GvHD is associated with significant morbidity and mortality, and generally results in poor outcomes. Salvage therapy for patients who fail steroid therapy is not well defined in the literature. In the current retrospective study, we reviewed our experience with the combination of basiliximab and infliximab in 21 patients with severe, grade III-IV GI acute GvHD of whom 16 met the definition for steroid-refractory disease. The overall response rate was 76%, with 43% CR at a median time of 21 days after beginning treatment. The survival at 1 year was 24%, with most deaths due to complications from GvHD and recurrence of primary disease. All five of the long-term survivors have chronic GvHD. On the basis of a review of the literature, this regimen does not seem to be significantly more effective than other strategies for severe GI GvHD and seems to be worse than the results reported for basiliximab alone. Future studies of single-agent basiliximab and newer agents are required.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center